432 Disruption of Dopaminergic Reactivity in Fibromyalgia Demonstrated by 11c‐raclopride/Pet

Wood, Patrick B.; Bushnell, M. Catherine; Jaeger, Erik; Haykemez, H.; Rabiner, Eugenii A.; Chizh, Boris A.

doi:10.1016/s1090-3801(06)60435-7

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reduction of dopamine metabolism in FMS has also been investigated using positron emission tomography scans [Wood et al 2006].…”

Section: Pathophysiology Of Fibromyalgia Syndromementioning

confidence: 99%

See 1 more Smart Citation

Sodium Oxybate: A Potential New Pharmacological Option for the Treatment of Fibromyalgia Syndrome

Swick¹

2011

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Fibromyalgia syndrome (FMS) is a common disorder, characterized by diffuse pain and tenderness, stiffness, fatigue, affective disorders and significant sleep pathology. A new set of diagnostic criteria have been developed which should make it easier for a busy clinician to diagnose the condition. US Food and Drug Administration (FDA) approved medications for the treatment of FMS have, for the most part, been geared to modulate the pain pathways to give the patient some degree of relief. A different kind of pharmacological agent, sodium oxybate (SXB), is described that is currently approved for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. SXB, an endogenous metabolite of the inhibitory neurotransmitter gamma-hydroxybutyrate, is thought to act independently as a neurotransmitter with a presumed ability to modulate numerous other central nervous system neurotransmitters. In addition SXB has been shown to robustly increase slow wave sleep and decrease sleep fragmentation. Several large clinical trials have demonstrated SXB's ability to statistically improve pain, fatigue and a wide array of quality of life measurements of patients with fibromyalgia. SXB is not FDA approved to treat fibromyalgia.

show abstract

“…The reduction of dopamine metabolism in FMS has also been investigated using positron emission tomography scans [Wood et al 2006].…”

Section: Pathophysiology Of Fibromyalgia Syndromementioning

confidence: 99%

“…Chronic stress produces a suppression of dopamine activity and may represent an important aspect of the pathophysiology of FMS. The reduction of dopamine metabolism in FMS has also been investigated using positron emission tomography scans [Wood et al 2006].…”

Section: Pathophysiology Of Fibromyalgia Syndromementioning

confidence: 99%

Sodium Oxybate: A Potential New Pharmacological Option for the Treatment of Fibromyalgia Syndrome

Swick¹

2011

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…This can be information on receptor density and distribution, endogenous neurotransmitter release, or both. As an example, the role of the endogenous opioid [58,59] and dopaminergic systems [60][61][62] in pain modulation and chronic pain states has been documented, with potential implications for new therapeutic approaches.…”

mentioning

confidence: 99%

Using objective markers and imaging in the development of novel treatments of chronic pain

Chizh¹,

Hobson²

2007

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Novel pharmacotherapy for fibromyalgia

Wood

Holman

Jones

2007

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Fibromyalgia is a common disorder that is characterized by chronic widespread pain, tenderness to light palpation, fatigue and sleep disturbances. The present lack of a well-accepted model of the disorder has hampered progress towards adequate treatment. A review of potential models to explain the pathophysiology underlying its primary symptom (i.e., chronic widespread pain) lends insight on the therapeutic potential of novel therapies. Following this, a mechanistic evaluation of those medications that are under consideration for the treatment of the disorder is offered. Adequate treatment will be likely to involve the identification of biologic subgroups within the greater fibromyalgia construct. Key insights from basic research are the basis for increased optimism for effective relief among patients and clinicians.

show abstract

432 Disruption of Dopaminergic Reactivity in Fibromyalgia Demonstrated by 11c‐raclopride/Pet

Cited by 3 publications

References 0 publications

Sodium Oxybate: A Potential New Pharmacological Option for the Treatment of Fibromyalgia Syndrome

Sodium Oxybate: A Potential New Pharmacological Option for the Treatment of Fibromyalgia Syndrome

Using objective markers and imaging in the development of novel treatments of chronic pain

Novel pharmacotherapy for fibromyalgia

Contact Info

Product

Resources

About